Reviva Pharmaceuticals Holdings Inc. Warrants (25/12/2025) RVPHW 深 滬
等待開盤 06-25 09:30:00 美东时间
0.003
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.003
- 總市值 2.77万
- 52周最高 0.3678
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.003
- 委 比 0.00%
- 總股本 923.17万
- 歷史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.003
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OTC Markets approves Reviva Pharmaceuticals for trading on OTCQB Venture Market
OTC Markets approves Reviva Pharmaceuticals for trading on OTCQB Venture Market OTC Markets Group said three companies were cleared to begin trading on its OTCQB Venture Market on May 18. The new OTCQB names include Reviva Pharmaceuticals, Uraniumx Discovery, zSpace. Disclaimer: This news brief was
05-19 12:36
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
Reviva Pharmaceuticals Holdings, Inc. announced that its CEO, Laxminarayan Bhat, PhD, will participate in a fireside chat with equity research analyst Jim Molloy at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026, from 2:40-3:00 PM ET. Investors can register and view the chat [here](https://www.globenewswire.com/Tracker?data=ZQ4QHba1Md3if_7dhLdM9sszgHH-KoFFIMzCc1ePqROgxr4lyJ_Yi1ukhjpyE4vSGuyaAKmi0kpuBvajVRQAuYoK1XTKns0tyHpbsZbxjcyO-X0...
05-18 12:00
Reviva Pharmaceuticals Q1 EPS $(0.46) Beats $(0.62) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.62) by 25.81 percent. This is a 82.31 percent increase over losses of $(2.60) per share
05-14 04:39
Reviva Pharmaceuticals To Be Delisted From Nasdaq On May 14
As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the "Company") was not in compliance with the requirement under Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Requirement") to maintain
05-13 20:28
Reviva Pharmaceuticals Holdings Inc <RVPH.OQ> expected to post a loss of 62 cents a share - Earnings Preview
Reviva Pharmaceuticals Holdings Inc expected to post a loss of 62 cents a share - Earnings Preview Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on May 13 (estimated) for the period ending March 31 2026 LSEG's mean an
05-11 19:36
Reviva Updates Brilaroxazine Strategy and Funding Outlook
Reviva Pharmaceuticals Holdings ( ($RVPH) ) just unveiled an announcement. On A...
04-15 20:28
Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA
Regulation FD Disclosure.On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") issued a letter to shareholders announcing certain business updates, including in connection with the
04-15 20:16
Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
04-08 21:20
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights March 30 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O : REVIVA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS REVIVA PHARMACEUTICALS FY NET INCOME USD -19.9 MILLION REVIVA PHARMACE
03-30 21:57
Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.10) by 455.88 percent. This is a 81.1 percent increase over losses of $(3.00) per
03-30 19:57
